Login to Your Account

Other News To Note

Wednesday, June 6, 2012
• BioAlliance Pharma SA, of Paris, said the FDA accepted for review its new drug application for Sitavig (acyclovir Lauriad) for recurrent orofacial herpes. The application was based on results from a Phase III study showing that a single application of the drug, marketed in Europe as Sitavir, significantly reduced the occurrence of vesicular lesions and crusts, their time to healing and the severity of symptoms.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription